Narcolepsy is a chronic disorder of sleep–wake regulation that leads to overwhelming daytime sleepiness and disturbed nighttime sleep. It reflects dysfunction of the brain systems that control sleep stages rather than a psychiatric problem; many reputable sources and clinicians emphasize that narcolepsy is a medical condition, not a mental illness (see discussion).

Core features and common symptoms

Typical symptoms include persistent excessive daytime sleepiness, sudden sleep episodes, and fragmented nighttime sleep. Many people with narcolepsy also experience:

  • Cataplexy — brief losses of muscle tone often triggered by strong emotions such as laughter or surprise; this sign distinguishes the classical form of narcolepsy (cataplexy).
  • Sleep paralysis — temporary inability to move when falling asleep or waking.
  • Hypnagogic or hypnopompic hallucinations — vivid dream-like experiences at sleep onset or upon awakening.
  • Interrupted or poor-quality nocturnal sleep despite daytime sleep attacks.

Causes and mechanisms

Narcolepsy arises from disruption in neuronal systems that stabilize wakefulness and REM sleep. The best-established biological finding is loss of hypocretin (also called orexin) producing neurons in the hypothalamus for the type associated with cataplexy. An autoimmune process is suspected in many cases, and specific genetic markers (for example certain HLA alleles) increase risk but are not solely causative. Overall, the condition is neurological in origin and involves the nervous system.

Types and diagnosis

Clinicians generally describe two main types: type 1 narcolepsy (with cataplexy or low hypocretin) and type 2 (without cataplexy). Diagnosis relies on clinical history combined with sleep testing: overnight polysomnography to exclude other sleep disorders, followed by the multiple sleep latency test (MSLT) to document rapid sleep onset and REM sleep during daytime naps. Measurement of cerebrospinal hypocretin can aid diagnosis in select cases.

Treatment and daily management

There is no cure, but symptoms are often manageable with a combination of pharmacological and behavioral approaches. Medications commonly used include wake-promoting agents (such as modafinil and related drugs), stimulants for severe sleepiness, and specific agents like sodium oxybate that reduce cataplexy and improve nighttime sleep. Scheduled short naps, consistent sleep routines, workplace or school accommodations, and education about safety (for example when driving) are important parts of care.

Epidemiology, history and social aspects

Narcolepsy is underdiagnosed worldwide; estimates suggest roughly 25–50 cases per 100,000 people, though figures vary by study and region. The disorder was first formally described in the late 19th century by Jean-Baptiste Gélineau. Because of unpredictable sleep attacks and cataplexy, there are practical and legal consequences for activities such as driving; rules differ by jurisdiction and some places restrict or require assessment before issuing a license (legal and safety guidance).

People with narcolepsy may face social and occupational challenges and higher rates of mood disorders; multidisciplinary care and public awareness can reduce stigma and improve outcomes. For general patient information and resources, see trusted medical and patient-advocacy platforms (overview, neuroscience context, cataplexy details, mental health context, driving guidance).